StockData
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc. (JANX) stock

JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3037% below fair value
$10.31−0.40 (-3.73%)

Close on Nov 18, 2026Market cap $630.32MP/E –Yield –

Janux Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Janux Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $24.00M, up 5367.0% year over year. For fiscal 2025 it was $10.00M, down 5.6% from the year before. The highest annual figure on record is $10.59M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.00M-5.6%
FY2024Dec 31, 2024$10.59M+31.0%
FY2023Dec 31, 2023$8.08M-6.1%
FY2022Dec 31, 2022$8.61M+136.8%
FY2021Dec 31, 2021$3.64M–
FY2020Dec 31, 2020$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$10.27M–
Q1 FY2026Mar 31, 2026$3.73M–
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$10.00M+2177.9%
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$0-100.0%
Q4 FY2024Dec 31, 2024$0-100.0%
Q3 FY2024Sep 30, 2024$439.00K-82.6%
Q2 FY2024Jun 30, 2024$8.90M+741.7%
Q1 FY2024Mar 31, 2024$1.25M-38.9%
Q4 FY2023Dec 31, 2023$2.46M-13.5%
Q3 FY2023Sep 30, 2023$2.52M+38.8%
Q2 FY2023Jun 30, 2023$1.06M-55.3%
Q1 FY2023Mar 31, 2023$2.05M+28.9%
Q4 FY2022Dec 31, 2022$2.85M+76.1%
Q3 FY2022Sep 30, 2022$1.81M+56.4%
Q2 FY2022Jun 30, 2022$2.37M+390.7%
Q1 FY2022Mar 31, 2022$1.59M+318.2%
Q4 FY2021Dec 31, 2021$1.62M–
Q3 FY2021Sep 30, 2021$1.16M–
Q2 FY2021Jun 30, 2021$482.00K–
Q1 FY2021Mar 31, 2021$380.00K–
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–

More Janux Therapeutics figures

See a number that looks wrong?